EUCTR2008-005872-29-NL进行中（未招募）不适用
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,080
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Female subjects =18 years of age
- •2.Subjects of childbearing potential must be surgically sterile or consent to use a medically acceptable method of contraception throughout the study period. Contraceptive measures must start either prior to or at screening and continue throughout the entire study period and for 2 months after the last dose of study drug is administered. Pregnant and/or lactating females are excluded
- •3.A histologically or cytologically confirmed diagnosis of non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignancies
- •4.Have been treated with debulking surgery and first–line platinum and taxane based chemotherapy
- •5.Prior bevacizumbab maintenance is allowed. The last dose of bevacizumab must have been at least 30 days before study Day 1. No cytotoxic maintenance therapy (e.g. taxane) or cancer vaccine therapy is allowed.
- •6.Must have measurable disease by CT or MRI scan
- •7.Must have relapsed radiologically with a randomization date within =6 and = 24 months of completion of first-line platinum/taxane chemotherapy
- •8.Must be a candidate for repeat carboplatin and taxane therapy
- •9.Life expectancy of =6 months as estimated by the investigator
- •10.Other significant medical conditions must be well-controlled and stable in the opinion of the investigator for at least 30 days prior to Study Day 1
- •11.Karnofsky performance status (KPS) =70%
- •12.Laboratory and clinical results within the 2 weeks prior to Study Day 1 as follows:
- •Absolute neutrophil count (ANC)= 1.5 x 10*9/L
- •Platelet count= 100 x 10*9/L
- •Hemoglobin= 9 g/dL
- •Creatinine=1.5x ULN (CTCAE Grade 1)
- •Bilirubin< 1.5x ULN (CTCAE Grade 1)
- •Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphatase< 2.5 x ULN (CTCAE Grade 1)
- •13.Neurologic function: neuropathy (sensory and motor) =CTCAE Grade 1
- •14.Subject must provide written informed consent and be able to comply with the protocol procedures
- •(*=to the power)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 360
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 720
排除标准
- •1.Subjects who never responded to first-line platinum-based therapy or whose first relapse occurs <6 months or >24 months from the last platinum therapy
- •2.Subjects who have received other therapy to treat their ovarian cancer since relapse
- •3.Known central nervous system (CNS) tumor involvement
- •4.Evidence of other active invasive malignancy requiring treatment in the past 5 years
- •5.Clinically significant heart disease (e.g., congestive heart failure of New York Heart Association Class 3 or 4 angina not well controlled by medication, or myocardial infarction within 6 months)
- •6.Electrocardiogram (ECG) demonstrating clinically significant arrhythmias (Note: subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia [SVT], are eligible)
- •7.Active serious systemic disease, including active bacterial or fungal infection
- •8.Active viral hepatitis or active human immunodeficiency virus (HIV) infection. Asymptomatic positive serology is not exclusionary.
- •9.Other concurrent immunotherapy (e.g., immunosuppressants or chronic use of systemic corticosteroids with the exception that low-dose corticosteroids are allowed)
- •10.Known allergic reaction to a prior monoclonal antibody therapy or have any documented
- •11.Previous treatment with MORAb-003 (farletuzumab)
- •12.Clinical contraindications to use of a taxane
- •13.Prior treatment with any investigational agent within 4 weeks of study entry
- •14.Breast-feeding, pregnant, or likely to become pregnant during the study
研究者
相似试验
进行中（未招募）
1 期
An experimental study in men and women with head and neck cancer to test the safety, tolerability and the effects of addition of a vaccine directed against an infection with Human Papilloma virus Type 16 (HPV16) in combination with an antibody that activate part of the immune systemEUCTR2018-000789-13-BEISA Therapeutics B.V.194
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First RelapseFirst relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignanciesMedDRA version: 9.1 Level: LLT Classification code 10033160 Term: Ovarian epithelial cancer recurrentEUCTR2008-005872-29-FREisai Limited
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First RelapseFirst relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignanciesMedDRA version: 9.1Level: LLTClassification code 10033160Term: Ovarian epithelial cancer recurrentEUCTR2008-005872-29-PTEisai Limited900
进行中（未招募）
1 期
An experimental study in men and women with head and neck cancer to test the safety, tolerability and the effects of addition of a vaccine directed against an infection with Human Papilloma virus Type 16 (HPV16) in combination with an antibody that activate part of the immune systemHPV16-Positive Oropharyngeal Cancer (OPC)MedDRA version: 21.0Level: PTClassification code 10031098Term: Oropharyngeal cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000789-13-CZISA Therapeutics B.V.194
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First RelapseFirst relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignanciesMedDRA version: 9.1Level: LLTClassification code 10033160Term: Ovarian epithelial cancer recurrentEUCTR2008-005872-29-GREisai Limited900